China Regenerative Medicine International

What China Regenerative Medicine International does

China Regenerative Medicine International Limited (CRMI) is a Hong Kong-listed (HKEX GEM: 8158) biotechnology company focused on the development, manufacture, and commercialization of regenerative medicine products. The company's portfolio centers on two core tissue-engineered products: Acornea, a bio-engineered cornea positioned as the world's first commercialized product of its kind, and ActivSkin, a tissue-engineered skin substitute. CRMI also operates adjacent business lines including cell storage and therapy, hospital administration services, and a consumer-facing cosmetics segment.

CRMI runs seven manufacturing facilities across mainland China, supported by ISO 9001 and ISO 13485 quality certifications, and maintains research collaborations including with Oxford University and CCB International. Its commercial model is B2B-oriented, selling primarily to hospitals, eye banks, and medical institutions in China, with provincial National Health Commission relationships cited and Acornea listed in the national medical insurance system as of 2018. The company is pursuing international expansion through partnerships in Egypt, Morocco, and Russia, and is pursuing FDA registration for Acornea.

CRMI's revenue model is anchored on per-unit medical-device sales (primarily Acornea) with demand elasticity shaped by insurance reimbursement levels and provincial hospital procurement. The company is in an early commercial stage relative to its pipeline ambition, with reported 41% year-over-year growth for the eight months ended December 2017 and a single dominant SKU. Operational complexity is elevated by multiple leadership transitions and a 2019 share consolidation following HKEX censure for listing-rule violations.

Name

China Regenerative Medicine International

Legal name

China Regenerative Medicine International Limited

Website

https://crmi.hk

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

251–500 employees

Short description

China Regenerative Medicine International (HKEX GEM: 8158) develops and manufactures tissue-engineered products including Acornea bio-engineered cornea and ActivSkin, selling primarily to hospitals and medical institutions in China with select international expansion.

Ownership category

akta.pro rank

Product category

Regenerative Medicine & Tissue Engineering

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industries

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Regenerative medicine products
• Tissue engineering products
• Bio-engineered cornea
• Stem cell services
• Cell therapy solutions

Headquarters

HQ city

Wan Chai

HQ country

Hong Kong SAR China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Tissue Engineering Products: Sale of tissue engineering and regenerative medicine products including bio-engineered cornea and tissue-engineered skin to medical institutions
2. Cell Storage Services: Cell storage services for stem cells and regenerative cells
3. Cell Preparation and Therapy: Preparation and therapy services using stem cells and regenerative medicine techniques
4. Cosmetics: Cosmetics products derived from regenerative medicine technology
5. Hospital Administration: Management and operation of hospitals and medical facilities
6. Overseas Business Division: International business division including overseas licensing and partnerships

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

CRMI researches, develops, manufactures and sells tissue engineering and regenerative medicine products, most notably the bio-engineered cornea Acornea and the tissue-engineered skin ActivSkin, supplying hospitals and medical institutions in China and internationally. The company also provides cell storage, preparation and therapy services, regenerative cosmetics under the Aomeiya brand, hospital administration services, and operates an overseas business division focused on international licensing and FDA registration.

Product overview

China Regenerative Medicine International operates as a diversified tissue engineering and regenerative medicine enterprise with a portfolio spanning five major business sectors: tissue engineering, cosmetics, cell storage and therapy, hospitals administration, and overseas business. The core tissue engineering products include Acornea (bio-engineered cornea) and ActivSkin (tissue engineered skin), while the cosmetics division features the Aomeiya brand. Additional products include Ruishuanning for anorectal applications and Morui membrane products. The company also operates cell storage and therapy services, with seven manufacturing facilities located across Xi'an, Shenzhen, Suzhou, Tianjin, Changzhou, and Hong Kong.

Differentiator

Problem solved

Functional benefit

Products and services

• Acornea (艾欣瞳) The world's first bio-engineered cornea for corneal transplantation, developed to treat corneal blindness and approved for clinical use in China. Sold to hospitals and ophthalmology institutions and integrated into mainland Chinese medical insurance.
• ActivSkin (安体肤) Tissue-engineered skin product for burn and chronic wound treatment, approved for clinical use in China and produced by subsidiary Shaanxi Elf Tissue Engineering.
• Aomeiya (艾美雅) High-end medical cosmetics brand offering regenerative skincare products derived from CRMI's tissue engineering technology for anti-aging and aesthetic consumers.
• Ruishuanning (瑞栓宁) Tissue engineering product for anorectal applications, presented at medical conferences and offered within CRMI's tissue engineering portfolio.
• Morui (膜瑞) Membrane-based tissue engineering product that passed registration quality system inspection, extending CRMI's tissue engineering product line.
• 3D Flo Cell Culture Instrument (3D Flo细胞培养仪) Cell culture equipment developed by subsidiary Tianjin Weikai Bioengineering, sold to research institutions including the US National Institutes of Health for 3D cell culture applications.
• Cell Storage Service Cell storage services for stem cells and regenerative cells, including the GMP cell processing platform at the Suzhou Aokai Cell Bank, for preservation and future therapeutic use.
• Cell Preparation and Therapy Services Cell preparation and therapy services using stem cells and regenerative medicine techniques for clinical applications, delivered through CRMI's GMP-certified cell processing platform.
• Hospital Administration Services Management and operation of hospitals and medical facilities, including the Hong Kong International Regenerative Medicine Center and presence at Boao Super Hospital.

Quantifiable outcome

• First bio-engineered cornea approved in China - addressing corneal blindness
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered major, minor and core.

• Shanghai Lingang Songjiang High-tech (上海临港松江高新产业)majorStrategic or Co-development Partner · 16 January 2018Strategic cooperation framework agreement for high-tech industrial development
• Huayuan Pharmaceuticals (华源医药)majorChannel Partner/ Reseller/ Distributor · 10 December 2017Framework agreement for acquisition to expand China's medical market sales network
• TopGene (拓普基因)minorStrategic or Co-development Partner · 30 October 2017Strategic cooperation for genetic testing and personalized medicine services
• National Engineering Research Center for Ophthalmology (国家眼科工程中心)coreStrategic or Co-development Partner · 28 July 2017Joint laboratory on regenerative medicine technology under the National Engineering Research Center for Ophthalmology to improve product technologies and facilitate ophthalmic technology development
• Shanghai International Medical Center (上海国际医学中心)majorStrategic or Co-development Partner · 8 June 2017Strategic cooperation agreement for medical services and regenerative medicine applications
• Egypt and Morocco (埃津两国)majorStrategic or Co-development Partner · 28 November 2016Framework agreement signed with Egypt and Morocco to jointly promote global pharmaceutical industry sustainable development in Africa
• Penza Government Russia & TITANMED (俄罗斯奔萨州政府及TITANMED)majorStrategic or Co-development Partner · 22 November 2016Trilateral strategic cooperation with Russian Pensa regional government and TITANMED for medical market development
• China National Medical Device Corporation (国药器材)majorStrategic or Co-development Partner · 19 September 2016Strategic cooperation for medical device distribution and market development in China
• Hainan Boao Special Zone (海南博鳌)coreStrategic or Co-development Partner · 11 April 2016Framework agreement to advance Hainan Boao Regenerative Medicine Research and Clinical Medical Center project; CRMI stationed as Hong Kong's only medical team at Boao Super Hospital
• Oxford University (牛津大学)coreStrategic or Co-development Partner · 19 January 2015Established China Biomedical Oxford University Technology R&D Center for tissue engineering product development and industrialization; Prof. Zhandong Cui serves as a key academician partner
• Wenzhou Medical University (温州医科大学)coreStrategic or Co-development Partner · 13 November 2014Cooperation agreement for tissue engineering skin product ActivSkin, including clinical research and product promotion

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Organogenesis Holdings: US-based regenerative medicine company specializing in advanced wound care and surgical biologics (e.g., Apligraf for skin regeneration). Directly comparable to CRMI's ActivSkin tissue-engineered skin product and overall regenerative medicine focus.
• Vericel Corporation: Commercial-stage developer of advanced cell therapies and regenerative medicine products for sports medicine and severe burn care. Comparable to CRMI in tissue engineering and burn/wound care focus, with overlapping product categories.
• MiMedx Group: Developer and marketer of regenerative medicine products using placental tissue for wound care and surgical applications. Directly comparable to CRMI's tissue-engineered skin and regenerative wound healing products.
• Anika Therapeutics: Joint preservation and regenerative medicine company developing hyaluronic acid-based products for tissue regeneration. Comparable to CRMI in regenerative medicine and tissue engineering focus, though in joint/orthopedic applications.

Broad incumbents

• Integra LifeSciences: Global medical technology company with a strong regenerative tissue technologies portfolio, including dermal regeneration templates. Competes with CRMI's ActivSkin and represents a much larger incumbent in the tissue engineering space.
• Smith+Nephew: Global medical device company with an advanced wound management division offering bioengineered skin substitutes and regenerative products. A broad incumbent competing with CRMI's wound care and tissue engineering products.
• Coloplast: Major wound and skin care company with biologic and tissue-engineered wound healing products. Comparable to CRMI's ActivSkin and regenerative wound care offerings as an established global player.
• ConvaTec: Global medical products and technologies company specializing in advanced wound care, ostomy, and skin substitutes. Comparable to CRMI in the wound healing and biologic skin substitute categories.

Emerging players

• CorNeat Vision: Israeli ophthalmological medical device company developing synthetic cornea implants (CorNeat KPro). Comparable to CRMI's Acornea bio-engineered cornea as a competing solution in the corneal blindness treatment space.
• Mesoblast: Australian regenerative medicine company developing cellular medicines for inflammatory diseases and tissue repair. Comparable to CRMI in stem cell and regenerative medicine technology platform, with overlap in cell-based therapy development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/china-regenerative-medicine-international

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about China Regenerative Medicine International